- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8 - K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (D)
Of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report: MAY 18, 2004
ENDOVASC, INC.
(Exact name of registrant as specified in its charter)
NEVADA
(State or other jurisdiction of incorporation or organization)
000-28371 76-0512500
(Commission File Number) (IRS Employer Identification Number)
DR. DIANE DOTTAVIO, PRESIDENT & CEO
ENDOVASC, INC.
550 CLUB DRIVE, SUITE 440
MONTGOMERY, TEXAS 77316
(Address of principal executive offices)
(936) 582-5920
(Registrant's telephone number, including area code)
550 CLUB DRIVE, SUITE 440
MONTGOMERY, TEXAS 77316
(Former name or former address, if changed since last report)
- --------------------------------------------------------------------------------
ITEM 5. OTHER EVENTS
- --------------------
Termination of Stentgenix Agreement
On April 27, 2004, the Company terminated its agreement with MIV Therapeutics,
Inc. (OTCBB: MIVT).
The Company entered into an agreement with MIV Therapeutics, Inc. in November of
2002, to develop Endovasc's Angiogenix (TM) and a biodegradable stent. Under
this agreement the Company was to contribute certain technology while MIV
Therapeutics, Inc. was to provide funding for the research. On November 17,
2003, MIV Therapeutics, Inc. was placed on notice that they were in default in
the funding of the agreement; because of this default Endovasc, Inc. did not
transfer the technology. MIV Therapeutics, Inc. has not been able to cure this
default, and the agreement was terminated April 27, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ENDOVASC, INC.
(A NEVADA CORPORATION)
By:
---------------------------------------------------------
Dr. Diane Dottavio, President and Chief Executive Officer
Date: May 18, 2004